That WISP2 has been reported to be possibly regulated by the typical Wnt and TGF-β pathways for treatment of obesity and metabolic diseases, and developing new therapeutic strategies (Grünberg et al., 2018). The gene discussed is TGFB1; the disease is metabolic disease.